BOIRON

Earnings Release • Apr 28, 2023

BOTRON®

April 27, 2023

2023 FIRST QUARTER BOIRON SALES

(Unaudited data)

In thousands of euros	2023	2027	Variation at	Variation at
			current	constant
			exchange rates	exchange rates
France	54,580	77,055	-29.2%	-29.2%
Europe (excluding France)	39,220	34,476	+13.8%	+9.0%
North America	33,279	28,944	+15.0%	+11.0%
Other countries	5,220	5,305	-1.6%	-3.9%
Group total	132,299	145,780	-9.2%	-11.2%
			Variation at	Variation at
In thousands of euros	2023	2022	current	constant
			exchange rates	exchange rates
Non-proprietary homeopathic medicines	45,234	45,516	-0.6%	-1.4%
Homeopathic specialties	80,055	67,100	+19.3%	+15.6%
Other health products	7,010	33,164	-78.9%	-79.0%
Group total	132,299	145,780	-9.2%	-11.2%

Change in sales

Sales for the first quarter of 2023 were down 9.2%, heavily impacted by a challenging basis for comparison due to strong COVID test sales in the first quarter of 2022. This decline in COVID test sales was primarily localized in France.

Excluding these tests, sales were up 10.6%.

Changes in non-proprietary homeopathic medicine sales were varied. They continued to decline in France while increasing in almost all other countries, particularly the United States.

Homeopathic specialty sales continued to grow in most countries, across all products. This performance is even more remarkable given that sales had already increased significantly in 2022.

Two new homeopathic medicines were launched in France during the first quarter: Prélinium®, traditionally used in the long-term treatment of seasonal allergic rhinitis, and Idryline®, eye drops developed for the symptoms of dry eye.

Outlook

In 2023, Group sales may be impacted by the decrease in COVID test sales, by pressure on the supply of raw materials and by the geopolitical situation in certain parts of the world. Nevertheless, upcoming launches and current momentum in homeopathic specialties enable us to maintain our target of increasing sales.

We continue to put all our energy and determination into ensuring that every patient in the world can take advantage of homeopathy and our other healthcare solutions, thereby supporting a more humane, efficient and sustainable healthcare system.

Laboratoires BOIRON

Our next updates:

• The Mixed Shareholders' Meeting will be held on Mat BOIRON headquarters, 2 wenve de l'Ouest Lyonnais, 69510 MESSMY FRANCE.
• June 2, 2023: ofter approval by the Mixed Shareholders' Meeting, payment of the proposed dividend (€1.10 per share).
• July 18, 2023: after the close of the stock market, publication of the sales on June 30, 2023.
• Person responsible for financial information: Valérie Lorentz-Poinsot

Contact for financial information: Fabrice Rey

ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA

lnvestor relations: +33 (0) 4.37.41.84.01 - e-mail: boironfinances@boiron.fr

The group's financial information is online at : www.boironfinance.com